Pharma BD Deal Intelligence

Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities)

2012 · Asset Purchase · $200M · Complete

Announcement Sentiment

Strongly positive

Hospira acquired Orchid's beta-lactam API manufacturing facility (Aurangabad, ~665 employees) and Chennai R&D site (~110 scientists) for ~$200M. Vertical integration into beta-lactam injectable antibiotics. Orchid retained cephalosporin API business and continued supply.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 10yr post-close.

Key facts

Announced Aug 09, 2012
Closed Dec 31, 2012
Deal value $200M
Deal type Asset Purchase
Therapeutic area Sterile beta-lactam antibiotic APIs (penems, penicillins)
Indications Sterile beta-lactam antibiotic APIs (penems, penicillins)
Key assets Beta-lactam API manufacturing (Aurangabad) + R&D (Chennai)
Mechanism Beta-lactam antibiotics

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals